![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
KL McCoy, D Gainey and GA Cabral
Department of Microbiology and Immunology, Medical College of Virginia, Virginia Commonwealth University, Richmond, USA.
delta 9-Tetrahydrocannabinol (THC) exposure suppresses multiple immunological functions of macrophages. The ability of macrophages exposed to THC to process and present soluble protein antigens was investigated by the stimulation of antigen-specific helper T cell hybridomas to secrete interleukin-2. The T cell response to hen egg lysozyme was dramatically reduced after a 24-hr pretreatment of a macrophage hybridoma with THC. In contrast, THC exposure did not alter the capacity of the macrophage hybridoma to process chicken ovalbumin and augmented their presenting cell function for a pigeon cytochrome c response. These findings could not be attributed to differential effects of THC on either cell viability or expression of the antigen receptor-associated CD3 complex by the T cells. The level of T cell activation with peptides of lysozyme and cytochrome c, which do not require processing, was inhibited only at the highest concentrations of THC, suggesting that THC mainly affects antigen processing. Peritoneal macrophages exposed to THC during an antigen pulse and fixed with paraformaldehyde showed similar effects on the subsequent T cell responses to lysozyme and cytochrome c in the absence of THC, arguing against a possible influence of THC on the T cells. Therefore, THC differentially modulates the capacity of macrophages to process antigens that is necessary for the activation of CD4+ T cells.
This article has been cited by other articles:
|
|
 |
|
  H. Xu, C. L. Cheng, M. Chen, A. Manivannan, L. Cabay, R. G. Pertwee, A. Coutts, and J. V. Forrester Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis J. Leukoc. Biol., September 1, 2007; 82(3): 532 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Cabral and F. Marciano-Cabral Cannabinoid receptors in microglia of the central nervous system: immune functional relevance J. Leukoc. Biol., December 1, 2005; 78(6): 1192 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Rayman, K. H. Lam, J. D. Laman, P. J. Simons, B. Lowenberg, P. Sonneveld, and R. Delwel Distinct Expression Profiles of the Peripheral Cannabinoid Receptor in Lymphoid Tissues Depending on Receptor Activation Status J. Immunol., February 15, 2004; 172(4): 2111 - 2117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Howlett, F. Barth, T. I. Bonner, G. Cabral, P. Casellas, W. A. Devane, C. C. Felder, M. Herkenham, K. Mackie, B. R. Martin, et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev., June 1, 2002; 54(2): 161 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Alberich Jorda, S. E. Verbakel, P. J. M. Valk, Y. V. Vankan-Berkhoudt, M. Maccarrone, A. Finazzi-Agro, B. Lowenberg, and R. Delwel Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol Blood, April 15, 2002; 99(8): 2786 - 2793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Malfait, R. Gallily, P. F. Sumariwalla, A. S. Malik, E. Andreakos, R. Mechoulam, and M. Feldmann The nonpsychoactive cannabis-constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis PNAS, July 30, 2000; (2000) 160105897. [Abstract] [Full Text]
|
|
|
|
|
|
L. X. Zhu, S. Sharma, M. Stolina, B. Gardner, M. D. Roth, D. P. Tashkin, and S. M. Dubinett {Delta}-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway J. Immunol., July 1, 2000; 165(1): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. McCoy, M. Matveyeva, S. J. Carlisle, and G. A. Cabral Cannabinoid Inhibition of the Processing of Intact Lysozyme by Macrophages: Evidence for CB2 Receptor Participation J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1620 - 1625. [Abstract] [Full Text]
|
|
|
|
|
|
P. Carayon, J. Marchand, D. Dussossoy, J.-M. Derocq, O. Jbilo, A. Bord, M. Bouaboula, S. Galiegue, P. Mondiere, G. Penarier, et al. Modulation and Functional Involvement of CB2 Peripheral Cannabinoid Receptors During B-Cell Differentiation Blood, November 15, 1998; 92(10): 3605 - 3615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Stefano, Y. Liu, and M. S. Goligorsky Cannabinoid Receptors Are Coupled to Nitric Oxide Release in Invertebrate Immunocytes, Microglia, and Human Monocytes J. Biol. Chem., August 9, 1996; 271(32): 19238 - 19242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Malfait, R. Gallily, P. F. Sumariwalla, A. S. Malik, E. Andreakos, R. Mechoulam, and M. Feldmann From the Cover: The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis PNAS, August 15, 2000; 97(17): 9561 - 9566. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
